Mizuho lowered the firm’s price target on HCA Healthcare to $275 from $325 and keeps a Buy rating on the shares. The analyst reduced 2023 and 2025 adjusted EBITDA estimates to reflect higher physician cost pressures than previously anticipated. However, the firm believes the risk is reflected in the stock’s current valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCA: